ArticleRadiation oncology (London, England)2025
Exploring a recurrence model for atypical meningioma based on multiparametric MRI radiomic and clinical characteristics: a multicenter retrospective cohort study.
Article in Radiation oncology (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Magnetic Resonance Imaging-Based Radiomic Signatures for the Diagnosis of Zoster-Associated Pain: A Quantitative Imaging Approach.Pain and therapy · 2026Article
- Are AI Neuroimaging Models Ready for Clinical Use? A Systematic Methodological Review.Journal of clinical medicine · 2026Review
- MRI and Meningioma Research: Hotspots and Trends via Bibliometric AnalysisCurrent medical imaging · 2026Article
- Advancements in the application of MRI radiomics in meningioma.Radiation oncology (London, England) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
objectivesAtypical meningioma (AM) has a high recurrence rate. This study explored the factors associated with recurrence and built a predictive model for AM by combining radiomic and clinical features.
methodsThis retrospective cohort study enrolled 451 adult AM patients who underwent surgical treatment at three institutions between May 2012 and April 2024. The patients in institution 1 were randomly assigned to the training dataset (n = 246) or internal validation dataset (n = 164) at a ratio of 6:4, and patients in institutions 2 and 3 composed the external validation dataset (n = 41). The clinical and pathological characteristics of the patients were collected, and radiomics technology was used to extract image features from preoperative multiparametric MR images. After feature screening, three types of AM recurrence prediction models were constructed: the radiomic model, the clinical model and the combined model.
resultsThe median follow-up time was 27 months, and 22.8% (n = 103) of the patients relapsed after surgery. A total of 23 radiomic features were included in the model. Compared with the radiomic model and clinical model, the combined model performed better in predicting recurrence, with C-index values of 0.8453, 0.7867 and 0.8125 in the training, internal validation and external validation datasets, respectively, and the AUC value remained above 0.85 within 5 years. The radiomics score plays the most important role in predicting the recurrence of AM, with features such as t1c_original_shape_MajorAxisLength and t1c_original_shape_Flatness being of high importance. Among the clinical features, secondary tumors, subtotal resection and high Ki-67 levels contribute to AM recurrence.
conclusionsRadiomics has additional value for predicting AM tumor recurrence and has favorable predictive performance when combined with clinical features.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.